ライフサイエンスコーパス: metabolic syndrome

1 ive genes and can be an adjunct treatment in metabolic syndrome.

2 el, capable of recapitulating key aspects of metabolic syndrome.

3 m use of JNK inhibitors for the treatment of metabolic syndrome.

4 rend toward a greater risk of posttransplant metabolic syndrome.

5 nd inflammatory pathways, which leads to the metabolic syndrome.

6 ised transaminases and 1 or more features of metabolic syndrome.

7 ditionally had either type 2 diabetes or the metabolic syndrome.

8 nesis and progression of hepatosteatosis and metabolic syndrome.

9 th manifestations of end-organ damage of the metabolic syndrome.

10 (6.5%) with gallstones and 986 (30.9%) with metabolic syndrome.

11 study adipose tissue and its implications in metabolic syndrome.

12 potentially at increased risk of developing metabolic syndrome.

13 iseases such as cancer, inflammation, or the metabolic syndrome.

14 nd tumor grade in the absence of obesity and metabolic syndrome.

15 to have a WHR above the thresholds used for metabolic syndrome.

16 , coinciding with the upsurge of obesity and metabolic syndrome.

17 animals presenting clinical features of the metabolic syndrome.

18 ose tissue inflammation and fibrosis and the metabolic syndrome.

19 h is usually associated with obesity and the metabolic syndrome.

20 olic stress and are thought to contribute to metabolic syndrome.

21 such as heart disease, type-2 diabetes, and metabolic syndrome.

22 n resistance and cardiometabolic function in metabolic syndrome.

23 ons and oxidative stress in Zucker rats with metabolic syndrome.

24 robiota and predispose SHRSP rats to develop metabolic syndrome.

25 getables, on liver steatosis associated with metabolic syndrome.

26 ion is associated with the increased risk of metabolic syndrome.

27 MIR122, might be developed for treatment of metabolic syndrome.

28 c steatosis, a precursor or manifestation of metabolic syndrome.

29 e inflammation in the context of obesity and metabolic syndrome.

30 ulum (ER) stress elicits EC dysregulation in metabolic syndrome.

31 d as a susceptibility locus for diabetes and metabolic syndrome.

32 s adiposity and the associated parameters of metabolic syndrome.

33 but do not have findings consistent with the metabolic syndrome.

34 nge of solutes and water under conditions of metabolic syndrome.

35 strategies for the treatment of obesity and metabolic syndrome.

36 biota as bioeffectors of message, leading to metabolic syndrome.

37 d profiles, may affect visceral fat mass and metabolic syndrome.

38 in diet-induced obese mice with pre-existing metabolic syndrome.

39 g therapeutic approach to reduce obesity and metabolic syndrome.

40 a encroachment and protected against LGI and metabolic syndrome.

41 rlying causes and progression of obesity and metabolic syndrome.

42 control cancer development in subjects with metabolic syndrome.

43 icture of NASH as the liver manifestation of metabolic syndrome.

44 obesity, dyslipidemia, type 2 diabetes, and metabolic syndrome.

45 ight individuals and those with diabetes and metabolic syndrome.

46 by NS imbalances, including galactosemia and metabolic syndrome.

47 omes, cancer, primary immune deficiency, and metabolic syndrome.

48 s of hyperinsulinemia on immunoregulation of metabolic syndrome.

49 epresent innovative approaches to manage the metabolic syndrome.

50 arn more about his ancestry and his risk for metabolic syndrome.

51 C risk with physical inactivity, obesity and metabolic syndrome.

52 eatment of pre-diabetes, type 2 diabetes and metabolic syndrome.

53 rs of systemic inflammation in patients with Metabolic Syndrome.

54 lude partial lipodystrophies associated with metabolic syndromes.

55 ts against high fat diet-induced obesity and metabolic syndromes.

56 s defense to autoimmune responses and immuno-metabolic syndromes.

57 e suitable potential therapeutic targets for metabolic syndromes.

58 Metabolic syndrome (13.5%; 44 of 326) was related to tra

59 se (42% vs. 34% vs. 31%, respectively), with metabolic syndrome (21% vs. 19% vs. 17%, respectively) a

60 , dyslipidemia (75.2%), obesity (76.6%), and metabolic syndrome (73%) were more prevalent in NAFLD th

61 Here, we review in detail how metabolic syndrome affects pulmonary vascular function.

62 It has been well documented that metabolic syndrome alters vascular endothelial and smoot

63 to characterize trends in the prevalence of metabolic syndrome among adults in the US between 2011 a

64 Psoriasis is associated with the metabolic syndrome, an interconnected group of condition

65 There was a positive association between metabolic syndrome and "advanced" periodontitis, when th

66 were 1.60 (95% CI 1.30-1.96; P < 0.001) for metabolic syndrome and 1.37 (1.03-1.82; P = 0.021) for t

67 min/1.73 m(2) [IQR, 95.7-113.0 mL], 9.7% had metabolic syndrome and 23% had advanced liver fibrosis (

68 amples obtained from 147 participants in the Metabolic syndrome and Atherosclerosis in South Asians L

69 with complications of obesity, including the metabolic syndrome and atherosclerosis.

70 l information about the relationship between metabolic syndrome and body composition compared with tr

71 ddition to showing the relationships between metabolic syndrome and body composition in a detailed an

72 Ortality RISk (AMORIS) (n = 528,580) and the Metabolic syndrome and Cancer project (Me-Can) cohorts (

73 promising target for treatment of diabetes, metabolic syndrome and cancer, but few GLUT5 inhibitors

74 t microbiota composition are associated with metabolic syndrome and chronic inflammatory diseases suc

75 Peripheral artery disease, common in metabolic syndrome and diabetes mellitus, responds poorl

76 robiota are being increasingly implicated in Metabolic Syndrome and Diabetes.

77 atic steatosis can be considered a marker of metabolic syndrome and diabetes.

78 The association between metabolic syndrome and DNA methylation is of great resea

79 a therapeutic approach for treatment of the metabolic syndrome and dyslipidemia, while avoiding syst

80 nectin as a key biological factor that links metabolic syndrome and emotional disorders.

81 oving glucose tolerance in diabetes mellitus/metabolic syndrome and enhancing satiety in obesity.

82 dered as severe hepatic manifestation of the metabolic syndrome and has alarming global prevalence.

83 which in turn can prevent or even treat the metabolic syndrome and hepatic steatosis.

84 Our findings for metabolic syndrome and high fasting blood glucose remain

85 is frequently associated with development of metabolic syndrome and insulin resistance, manifests whe

86 gate the relation of AT APOM expression with metabolic syndrome and insulin sensitivity, and study th

87 .5), and temperature with the development of metabolic syndrome and its components.

88 .Fatty liver is one of the major features of metabolic syndrome and its development is associated wit

89 ng pathway, which prevented many features of metabolic syndrome and liver steatosis that developed in

90 ons constitute the main risk factors for the metabolic syndrome and NAFLD.

91 genetic, dietary, or environmental model of metabolic syndrome and NAFLD.

92 6874 men and women aged 55 to 75 years with metabolic syndrome and no cardiovascular disease were en

93 heat consumption exacerbated features of the metabolic syndrome and non-alcoholic steatohepatitis, de

94 re divided into four phenotypes according to metabolic syndrome and obesity status: 1378 participants

95 ones in younger people (< 50 years old) with metabolic syndrome and obesity.

96 e is associated with disparities observed in metabolic syndrome and other obesity-associated diseases

97 d not only to cognitive impairment, but also metabolic syndrome and psychiatric illness including dep

98 exposed to MHFD during lactation display the metabolic syndrome and schizophrenia-like phenotype.

99 ation between subclinical hypothyroidism and metabolic syndrome and selected components.

100 he essential link between gut microbiota and metabolic syndrome and suggest that the preservation of

101 gests low-grade inflammation as the cause of metabolic syndrome and suggests diet as a promoter of ch

102 endocrine diseases, including osteoporosis, metabolic syndrome and type 2 diabetes mellitus, as well

103 an individuals, and reduced in subjects with metabolic syndrome and type 2 diabetes.

104 et for treating disordered energy metabolism metabolic syndrome and type 2 diabetes.

105 obiota was associated with increased risk of metabolic syndrome and VAT accumulation, particularly in

106 sociations were only partly explained by the metabolic syndrome and visceral adiposity, suggesting a

107 sease (such as obesity, type 2 diabetes, and metabolic syndrome), and male biological sex produce a d

108 den, which is common to periodontal disease, metabolic syndrome, and adverse pregnancy outcomes.

109 ention as a risk factor for cardiac disease, metabolic syndrome, and cerebrovascular disease.

110 luding infertility, cardiovascular diseases, metabolic syndrome, and decreased libido and sexual func

111 teatosis is the hepatic manifestation of the metabolic syndrome, and decreases the liver's ability to

112 Periodontal disease is associated with metabolic syndrome, and during pregnancy, it is linked t

113 henotypes of early-onset atherosclerosis and metabolic syndrome, and identified novel loss-of-functio

114 g the development of cardiovascular disease, metabolic syndrome, and immune dysfunction.

115 ment of inflammatory bowel diseases, cancer, metabolic syndrome, and neuropsychiatric disorders.

116 roved childhood (catch-up) growth, and adult metabolic syndrome; and survival differences between chi

117 y effects against crucial enzymes related to metabolic syndrome, antimicrobial potential, and in vitr

118 ic treatments used for the components of the metabolic syndrome appear to be insufficient to control

119 diet and host physiology that predispose to metabolic syndrome are incompletely understood.

120 n and optimal treatment of the components of metabolic syndrome are key in reducing the risk of these

121 Age, obesity, and metabolic syndrome are known risk factors for gallstones

122 Recipients with metabolic syndrome are up to four times more likely to h

123 aternal factors, such as age and features of metabolic syndrome, are associated with risk of autism s

124 Mice with deletion of SERT develop metabolic syndrome as they age.

125 apeutic strategies to treat individuals with metabolic syndrome, as RXR heterodimerizes with multiple

126 ratory fitness compared with obesity and the metabolic syndrome, as well as the increase of physical

127 0), a transcriptional co-regulator linked to metabolic syndromes associated with obesity, and Flt1.

128 he non-digested and digested samples towards metabolic syndrome-associated enzymes (alpha-amylase, al

129 Metabolic syndrome at the age of 23 years was measured u

130 raction was confirmed in the cross-sectional Metabolic Syndrome Berlin Potsdam study (p = 0.012), wit

131 mia, obesity, type 2 diabetes, hypertension, metabolic syndrome), but the mechanism underlying these

132 Impaired insulin signalling leads to metabolic syndrome, but the regulation of this process i

133 of several inflammatory diseases, including metabolic syndrome, but the underlying mechanisms are in

134 aviour will be vital in reducing obesity and metabolic syndrome, but we lack a standard model that ca

135 When we divided the metabolic syndrome by its components, we found that part

136 is less information available regarding how metabolic syndrome can affect pulmonary vascular functio

137 tions of drinkers had obesity, diabetes, and metabolic syndrome compared with nondrinkers (P < .01).

138 duals have lower MetScores, fewer individual metabolic syndrome components, and lower fatness than un

139 udies define MHO as having either 0, 1, or 2 metabolic syndrome components, whereas many others defin

140 le with obesity have a normal HOMA-IR and no metabolic syndrome components.

141 of this study are to (i) examine a clustered metabolic syndrome composite score (MetScore) and fatnes

142 ndrome signs and score lower on a continuous metabolic syndrome composite.

143 function and the whole-body MRI depiction of metabolic syndrome consequences were also noteworthy.

144 , being overweight or obese, presence of the metabolic syndrome, current treatment with atorvastatin

145 Metabolic syndrome defines a cluster of interrelated ris

146 Metabolic syndrome definition was the presence of >=3 of

147 vels of complement C2 resembling findings in metabolic syndrome, diabetes and other non-communicable

148 d cardiometabolic conditions (e.g., obesity, metabolic syndrome, diabetes) and represent a promising

149 ceptor antagonists may be useful in treating metabolic syndrome, diabetes, liver diseases, and gastro

150 In women, metabolic syndrome diagnosis was linked to regional diff

151 yle, and Genetic determinants of Obesity and Metabolic syndrome (DILGOM) cohort (n = 2982; age range:

152 festyle factors that are associated with the metabolic syndrome, disruption of the circadian system,

153 was associated with a 2-fold excess risk of metabolic syndrome, driven by increase in Desulfovibrion

154 t been approved for clinical trials to treat metabolic syndrome due to the serious side effects such

155 Metabolic syndrome encompasses obesity, glucose intolera

156 We report that parental metabolic syndrome epigenetically reprograms members of

157 obesity epidemic and increasing incidence of metabolic syndrome fatty liver disease now affects a lar

158 discuss the management of the components of metabolic syndrome following liver transplantation and p

159 ganogenesis in offspring and in predisposing metabolic syndrome for adult life.

160 College completion is associated with lower metabolic syndrome for whites across all levels of child

161 estyle factors that are known to promote the metabolic syndrome generally cause pro-inflammatory alte

162 The metabolic syndrome has direct effects on health and incr

163 Metabolic syndrome has increased at a worrisome level.

164 associated with a higher risk of developing metabolic syndrome (hazard ratio (HR) = 1.27, 95% confid

165 they typically manifest a severe form of the metabolic syndrome, highlighting the importance of white

166 est quartile (Q) of DII and the incidence of metabolic syndrome (HRQ4vsQ1 = 1.99; 95% CI: 1.03, 3.85;

167 highly inflammatory diet is associated with metabolic syndrome, hypertension, abdominal obesity, and

168 WD) leads to an elevated risk of obesity and metabolic syndrome in both males and females.

169 ive human milk feeding and blood pressure or metabolic syndrome in childhood.

170 erties that are associated with diabetes and metabolic syndrome in humans.

171 in the European ancestry individuals in the Metabolic Syndrome in Men (METSIM) cohort for trans-ethn

172 sis of metabolites by leveraging the Finnish Metabolic Syndrome In Men (METSIM) cohort, a unique gene

173 adipose tissue from 770 participants in the Metabolic Syndrome in Men (METSIM) study and detected 15

174 ed 5,181 participants of the cross-sectional METabolic Syndrome In Men (METSIM) study having metabolo

175 ons in the cross-sectional, population-based Metabolic Syndrome in Men cohort (n = 1337).

176 en inflammatory diets and the development of metabolic syndrome in Mexican adults.

177 c neuropeptide, QRFP, that might explain the metabolic syndrome in narcolepsy.

178 copper were the independent risk factor for metabolic syndrome in normal weight subjects.

179 dels directly impacts the risk of developing metabolic syndrome in obesity.

180 balance, gut microbiota, and risk factors of metabolic syndrome in spontaneously hypertensive stroke-

181 odulate gut microbiota and predisposition to metabolic syndrome in spontaneously hypertensive stroke-

182 hat individuals who present with features of metabolic syndrome in the presence of elevated liver enz

183 of childhood disadvantage for depression and metabolic syndrome in young adulthood, across race/ethni

184 d consequent obesity and insulin resistance (metabolic syndrome) in the recent increase in prevalence

185 asthma pathogenesis in patients with obesity/metabolic syndrome, in which the GRK2-mediated signaling

186 The primary risk factors of metabolic syndrome include hyperglycaemia, abdominal obe

187 Factors of metabolic syndrome including hyperinsulinemia and obesit

188 esistance and various other complications of metabolic syndrome, including diabetes, atherosclerosis,

189 bolic stress and promotes the development of metabolic syndrome, including hyperglycemia, hyperlipide

190 is D is associated with many features of the metabolic syndrome, including non-alcoholic fatty liver

191 NASH mice demonstrated key components of the metabolic syndrome, including obesity and impaired gluco

192 mproves human health with protection against metabolic syndromes, including type 2 diabetes; however,

193 Metabolic syndrome increases the risk of severe disease

194 to sunset in the prevention and treatment of metabolic syndrome-induced cancers.

195 nal microbiota are sufficient to promote the metabolic syndrome, inflammation and cancer.

196 The progressive relation among metabolic syndrome, insulin resistance (IR), and dementi

197 Metabolic syndrome is a critically important precursor t

198 Metabolic syndrome is a significant risk factor for seve

199 Although the reported prevalence of metabolic syndrome is approximately 30% worldwide, its p

200 Metabolic syndrome is characterized by central obesity,

201 Metabolic syndrome is characterized by disturbances in g

202 Metabolic syndrome is positively associated with "advanc

203 The metabolic syndrome is prevalent in developed nations and

204 Background The metabolic syndrome is related to obesity and ectopic fat

205 cle venular function with development of the metabolic syndrome, issues such as aggregate microvascul

206 and this can reduce the risk of obesity and metabolic syndrome later in life.

207 sociated with adverse pregnancy outcomes and metabolic syndrome later in maternal and fetal life, the

208 sulin resistance, beta-cell dysfunction, and metabolic syndrome, leading to cardiovascular disease.

209 of Gprc6a in mice is reported to result in a metabolic syndrome-like phenotype and conditional deleti

210 vere metabolic disorders, including obesity, metabolic syndrome, lipodystrophy, and cachexia.

211 adiposity; and we examined the prevalence of metabolic syndrome mediated by abdominal adiposity.

212 teria (CAF) diet fed rats, a robust model of metabolic syndrome (MeS), were administered 1000mg/kg of

213 prenorphine had significantly lower rates of metabolic syndrome (MetS) along with better values of th

214 The relationship between metabolic syndrome (MetS) and Barrett's esophagus (BE) i

215 rent types of plant-based diets and incident metabolic syndrome (MetS) and components of MetS.

216 density lipoproteins (VLDL) is a hallmark of metabolic syndrome (MetS) and each manifestation of MetS

217 tic protein-9(BMP-9) levels in subjects with Metabolic Syndrome (MetS) and examine the relationship b

218 aimed to investigate the association between metabolic syndrome (MetS) and periodontitis among young

219 However, the relationship between metabolic syndrome (MetS) and periodontitis remains cont

220 sulin in childhood and their impact on adult metabolic syndrome (MetS) and type 2 diabetes mellitus (

221 The role of metabolic syndrome (MetS) as a preceding metabolic state

222 The metabolic syndrome (MetS) encompasses medical conditions

223 Metabolic syndrome (MetS) has been associated with chron

224 Metabolic syndrome (MetS) is a cluster of interrelated r

225 The metabolic syndrome (MetS) is a constellation of risk fac

226 Metabolic syndrome (MetS) is one of the risk factors for

227 Metabolic markers associated with the Metabolic Syndrome (MetS) may be affected by interaction

228 at baseline in individuals with established metabolic syndrome (MetS) or diabetes identifies CHD and

229 Metabolic syndrome (MetS) represents a cluster of metabo

230 ge lean body mass at age 16/17 y; and with a metabolic syndrome (MetS) score and its components at ag

231 Metabolic syndrome (MetS) was defined with the joint IDF

232 matter hyperintensity (WMH) development: in metabolic syndrome (MetS), higher WMH load is often repo

233 dies have discussed on its relationship with metabolic syndrome (MetS).

234 e observed the development of age-associated metabolic syndrome (MetS).

235 PH due to LHD is often associated with metabolic syndrome (MetS).

236 pometric measurements in older subjects with metabolic syndrome (MetS).

237 n Italian population of patients affected by metabolic syndrome (MetS).

238 tohepatitis, which is a manifestation of the metabolic syndrome (MetS).

239 ent of multifunctional ingredients targeting metabolic syndrome (MetS).

240 ght/obese Spanish adults (aged 55-75 y) with metabolic syndrome (MetS).

241 atic vessels from high-fructose diet-induced metabolic syndrome (MetSyn) rats exhibited impairments i

242 In order toevaluate the influence of the metabolic syndrome (MS) (obesity, hypertension, elevated

243 Metabolic syndrome (MS) contributes to the risk for card

244 Although metabolic syndrome (MS) is a significant risk of cardiov

245 2 diabetes mellitus, hypertension (HT), and metabolic syndrome (MS) were investigated.

246 ty liver disease (NAFLD) parameters, such as metabolic syndrome (MS), inflammatory cytokines (tumor n

247 This study evaluated the risk factors for metabolic syndrome (MS), its components, and other assoc

248 h conventional medical care in patients with metabolic syndrome (MS).

249 ruption is associated with sleep deficiency, metabolic syndrome, neurological and psychiatric disorde

250 d to a broad range of problems including the metabolic syndrome, obesity, cancer, mental health disor

251 of metabolic risk factors for HCC, including metabolic syndrome, obesity, type II diabetes and non-al

252 by elevated blood pressure, and a prominent metabolic syndrome of modern age.

253 ders, the impact of paternal and/or maternal metabolic syndrome on the clinical phenotypes of offspri

254 have mixed or multiple risk factors such as metabolic syndrome or an estimated 10-year CVD risk of 7

255 ut diabetes, hypertension, dyslipidemia, the metabolic syndrome or impaired renal function.

256 so been described, such as the prevention of metabolic syndrome or type 2 diabetes.

257 ly associated with a higher incidence of the metabolic syndrome (OR=2.49; 95% CI 1.30-4.77), a steepe

258 ess and risk for hypertension, diabetes, and metabolic syndrome over the course of 25 years among 199

259 ty (P = 0.011; OR, 6.01; 95% CI, 1.51-23.9), metabolic syndrome (P = 0.016; OR, 5.87; 95% CI, 1.38-24

260 Among adults with the metabolic syndrome, PAB plasma concentrations were assoc

261 ch their circulating levels are increased in metabolic syndrome patients.

262 a potential treatment, the pNaKtide, for the metabolic syndrome phenotype.

263 hallmark clinical characteristics alongside metabolic syndrome phenotypes, including a propensity fo

264 ly significant fraction of the difference in metabolic syndrome prevalence, compared with white perso

265 n to predispose to obesity and the so-called metabolic syndrome provides further biological support f

266 Posttransplant metabolic syndrome (PTMS) was most frequent in lung (43%

267 ansplant is a risk factor for posttransplant metabolic syndrome (PTMS), cardiovascular events, and re

268 Voxel-wise analysis found metabolic syndrome related to liver, heart, and perirena

269 large reductions in the use of treatment of metabolic syndrome-related conditions, inhalants for obs

270 ustained decreases occurred for treatment of metabolic syndrome-related conditions, such as any gluco

271 ipants developed hypertension, diabetes, and metabolic syndrome, respectively.

272 ), insulin sensitivity index (p<0.0001), and metabolic syndrome score (p<0.0001) relative to control.

273 lipids; high-sensitivity C-reactive protein; metabolic syndrome score; and glucose homoeostasis measu

274 Adipose tissue, a key organ in metabolic syndrome, shows evident gender disparities in

275 pensatory beta-cell activity, and have fewer metabolic syndrome signs and score lower on a continuous

276 Diabetes mellitus, hypertension, metabolic syndrome, smoking, hyperlipidemia, and a seden

277 ective sample of 407 patients diagnosed with metabolic syndrome studied by MRI in a single center dur

278 nsidering the prevalence of complications of metabolic syndrome, such as non-alcoholic fatty liver di

279 r predictors of whether someone will develop metabolic syndrome than metabolites commonly used as bio

280 with class III obesity had a greater risk of metabolic syndrome than those with classes I/II [relativ

281 ow-grade chronic inflammation culminate into metabolic syndrome that increase the risk for the develo

282 Amidst the global rise in metabolic syndrome, the discovery of novel signaling rol

283 e food-derived mixtures to alleviate chronic metabolic syndrome through potential synergistic interac

284 Factors that underlie the clustering of metabolic syndrome traits are not fully known.

285 with prevalent insulin resistance, obesity, metabolic syndrome, type 2 diabetes, and an adverse lipi

286 Metabolic syndrome was diagnosed by the harmonized Natio

287 Criteria for posttransplant metabolic syndrome was met in 34.6% of EW versus 17.6% o

288 To assess the risk of metabolic syndrome we estimated HRs and 95% CIs using Co

289 intermittent fasting from dawn to sunset in metabolic syndrome, we conducted a pilot study in 14 sub

290 controlling for risk factors, patients with metabolic syndrome were at a 21% excess risk of developi

291 racts could help mitigate the development of metabolic syndrome where EAEP and AEP skim proteins coul

292 ized intervention including individuals with metabolic syndrome, where the healthy Nordic diet (HND)

293 mitral regurgitation, as well as features of metabolic syndrome, which include obesity, diabetes and

294 Aging is associated with inflammation and metabolic syndrome, which manifests in the liver as nona

295 ximately 40% of participants had undiagnosed metabolic syndrome, which was twice as common among male

296 conducted a pilot study in 14 subjects with metabolic syndrome who fasted (no eating or drinking) fr

297 characterized by muscle wasting, is a lethal metabolic syndrome with undefined etiology.

298 characterized by muscle wasting, is a lethal metabolic syndrome without defined etiology or establish

299 ecule, UAB126, which has positive effects on metabolic syndrome without the known side effects of pot

300 inflammation and diet in the development of metabolic syndrome; yet, a reduction in dietary componen